Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in mCRPC with dMMR or CDK12 Inactivation
NCT04104893Phase 2Active, not recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Feb 2020
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by VA Office of Research & Development. Started Feb 2020; status: active, not recruiting.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04104893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104893.